Innovent Biologics Statistics

Total Valuation

Innovent Biologics has a market cap or net worth of HKD 57.65 billion. The enterprise value is 51.98 billion.

Market Cap	57.65B
Enterprise Value	51.98B

Important Dates

The last earnings date was Thursday, November 28, 2024.

Earnings Date	Nov 28, 2024
Ex-Dividend Date	n/a

Share Statistics

Innovent Biologics has 1.64 billion shares outstanding. The number of shares has increased by 5.12% in one year.

Current Share Class	n/a
Shares Outstanding	1.64B
Shares Change (YoY)	+5.12%
Shares Change (QoQ)	+2.45%
Owned by Insiders (%)	6.76%
Owned by Institutions (%)	41.90%
Float	1.43B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.04
PB Ratio	4.29
P/TBV Ratio	4.69
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-37.75
EV / Sales	6.49
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-72.65

Financial Position

The company has a current ratio of 2.68, with a Debt / Equity ratio of 0.27.

Current Ratio	2.68
Quick Ratio	2.42
Debt / Equity	0.27
Debt / EBITDA	n/a
Debt / FCF	-5.03
Interest Coverage	-14.79

Financial Efficiency

Return on equity (ROE) is -11.04% and return on invested capital (ROIC) is -5.32%.

Return on Equity (ROE)	-11.04%
Return on Assets (ROA)	-4.18%
Return on Capital (ROIC)	-5.32%
Revenue Per Employee	1.52M
Profits Per Employee	-261,608
Employee Count	4,872
Asset Turnover	0.39
Inventory Turnover	2.13

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -11.08% in the last 52 weeks. The beta is 0.12, so Innovent Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.12
52-Week Price Change	-11.08%
50-Day Moving Average	39.00
200-Day Moving Average	39.64
Relative Strength Index (RSI)	35.85
Average Volume (20 Days)	7,499,374

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Innovent Biologics had revenue of HKD 8.01 billion and -1.38 billion in losses. Loss per share was -0.86.

Revenue	8.01B
Gross Profit	5.73B
Operating Income	-1.37B
Pretax Income	-1.38B
Net Income	-1.38B
EBITDA	-1.06B
EBIT	-1.37B
Loss Per Share	-0.86

Full Income Statement

Balance Sheet

The company has 9.27 billion in cash and 3.60 billion in debt, giving a net cash position of 5.67 billion or 3.46 per share.

Cash & Cash Equivalents	9.27B
Total Debt	3.60B
Net Cash	5.67B
Net Cash Per Share	3.46
Equity (Book Value)	13.35B
Book Value Per Share	8.20
Working Capital	7.44B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 596.42 million and capital expenditures -1.31 billion, giving a free cash flow of -715.54 million.

Operating Cash Flow	596.42M
Capital Expenditures	-1.31B
Free Cash Flow	-715.54M
FCF Per Share	-0.44

Full Cash Flow Statement

Margins

Gross margin is 71.58%, with operating and profit margins of -17.13% and -17.18%.

Gross Margin	71.58%
Operating Margin	-17.13%
Pretax Margin	-17.18%
Profit Margin	-17.18%
EBITDA Margin	-13.28%
EBIT Margin	-17.13%
FCF Margin	n/a

Dividends & Yields

Innovent Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.12%
Shareholder Yield	-5.12%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Innovent Biologics has an Altman Z-Score of 3.77.

Altman Z-Score	3.77
Piotroski F-Score	n/a